Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Liabilities and Shareholders Equity (2019 - 2025)

Vivos Therapeutics' Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $25.2 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $25.2 million for Q4 2025, up 64.56% from a year ago — trailing twelve months through Dec 2025 was $88.1 million (up 51.19% YoY), and the annual figure for FY2025 was $25.2 million, up 64.56%.
  • Liabilities and Shareholders Equity for Q4 2025 was $25.2 million at Vivos Therapeutics, down from $25.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $46.2 million in Q2 2021 to a low of $10.3 million in Q3 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $17.8 million (2022), against an average of $21.4 million.
  • The sharpest move saw Liabilities and Shareholders Equity plummeted 59.27% in 2022, then surged 67.09% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $33.7 million in 2021, then plummeted by 59.27% to $13.7 million in 2022, then dropped by 21.79% to $10.7 million in 2023, then soared by 42.44% to $15.3 million in 2024, then skyrocketed by 64.56% to $25.2 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $25.2 million, $25.6 million, and $26.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.